DYRK1A and intestinal cancer: In the ApcMin/+ model, the absence of ADAM17 resulted in a reduction in tumor formation in mouse intestinal cancer, highlighting the crucial role of ADAM17 in maintaining Wnt pathway activity.[49] Initially, adavivint was discovered to block the Wnt pathway by suppressing CLK2 and DYRK1A, and has advanced phase II clinical trials for knee osteoarthritis treatment.[22, 24] In this study, we identified 1837 proteins using MS analysis; CLK2 and DYRK1A were not detected.